FAS started reversing decisions on approved overrated drug prices

The Federal Antimonopoly Service (FAS Russia) abolishes decisions on approved maximum ex-works prices for expensive medicinal drugs registered in Russia at overrated prices

The abolishment concerns an Indian drug - “Imatinib” (“Imatinib” International Non-Proprietary Name). The price for the drug in Russia was overrated because the applicant submitted incorrect data regarding prices in the manufacturing country – India.

Having completed an investigation, FAS established that officially registered prices for this drug in India are nearly ten times less that stated by the applicant.

The Antimonopoly Service abolishes the decision on agreeing upon the price for “Imatinib” based on Clause 25 of the Rules introduced by No. 979 Decree of the Government of the Russian Federation of 15 September 2015. According to the Rules, the Ministry of Health Care of the Russian Federation must abolish the decision on state registration of the maximum ex-works manufacturer’s price for the drug and exclude the registered maximum ex-work price from the State Register.

“In the course of the investigation, FAS exposed a number of expensive drugs registered in Russia at overrated prices. Practically all companies reduced prices to the minimum level at the reference countries. FAS has to abolish the relevant decisions on agreed overrated prices with regard to the companies that refused to meet the requirements set in the Decree of the Government of the Russian Federation on price registration”, commented Head of FAS Department for Control over Social Sphere and Trade, Timophey Nizhegorodtsev.